Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

2009

Leukemia , Volume 23 - Issue 3 p. 627- 629

Additional Metadata
Keywords	BCR ABL protein, NUP214 protein, T cell leukemia, T lymphoblast, absence of side effects, acute lymphoblastic leukemia, adult, article, asparaginase, cancer regression, case report, chronic myeloid leukemia, cyclophosphamide, cytarabine, cytogenetics, dasatinib, daunorubicin, erythrocyte transfusion, febrile neutropenia, fluorescence in situ hybridization, fusion gene, gene amplification, human, imatinib, lymphocytic infiltration, male, methotrexate, mitoxantrone, mucosa inflammation, multiple cycle treatment, prednisone, priority journal, protein tyrosine kinase, recombinant granulocyte colony stimulating factor, thrombocyte transfusion, unclassified drug, vincristine
Persistent URL	doi.org/10.1038/leu.2008.318, hdl.handle.net/1765/18112
Journal	Leukemia
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Deenik, W., Beverloo, B., van der Poel-van de Luytgaarde, S., Wattel, M. M., van Esser, J., Valk, P., & Cornelissen, J. (2009). Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia, 23(3), 627–629. doi:10.1038/leu.2008.318

Publication